KYNB Share Price Performance
US$7.13
-0.75 (-9.46%)
83.4% undervalued intrinsic discount
US$43.00
Fair Value
Price US$7.13
AnalystConsensusTarget US$43.00
Fair ValueUS$43.00
Share Pricen/a
Kyntra Bio, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 4 Fair Values set on narratives written by author
KYNB Community Narratives
AN
Fair Value US$43 83.4% undervalued intrinsic discount
Clinical Trials And Regulatory Advances Will Open US Markets
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Clinical Trials And Regulatory Advances Will Open US Markets
Key Takeaways Advancing precision oncology and rare disease treatments positions the company for future revenue growth and strong market opportunities in underserved populations. Liquidity improvements and strategic pipeline diversification reduce financial risk while enhancing long-term earnings stability and optionality.Read more
55
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$43
83.4% undervalued intrinsic discount
Fair Value
Profit Margin
16.06%
Future PE
216.47x
Price in 2028
US$55.54
Trending Discussion
Recently Updated Narratives
AN
Clinical Trials And Regulatory Advances Will Open US Markets
Fair Value: US$43 83.4% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Kyntra Bio, Inc. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -14.38
- -273.80%
- -903.79%
- 437.1%
About KYNB
- Founded
- 1993
- Employees
- 225
- CEO
- WebsiteView website
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
